-
Innovation Ranking
Innovation Ranking – iBio Inc
iBio Inc (iBio) is a biotechnology company. It develops and manufactures plant made pharmaceutical products. The company provides products such as biotherapeutics and vaccines. Its pipeline products includes IBIO-100, IBIO-202 for Covid-19 and IBIO-400 for classical swine fever. The company's IBIO-100 is helpful for the treatment of idiopathic pulmonary fibrosis, fibrotic diseases and systemic sclerosis, among others. In addition, it is producing animal-free proteins using the FastPharming System. iBio offers CDMO services comprise of process development, cGMP manufacturing, aspetic fill,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ravulizumab LA in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ravulizumab LA in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ravulizumab LA in Lupus Nephritis Drug Details: Ravulizumab (Ultomiris) is a...
-
Product Insights
NewAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) – Drugs In Development, 2024
Empower your strategies with our Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) – Drugs In Development, 2024 report and make more profitable business decisions. Anti-neutrophil cytoplasmic antibody-associated (ANCA) vasculitis is a group of autoimmune diseases that cause inflammation and damage to small blood vessels. It is triggered by autoantibodies called ANCAs that target and attack neutrophils, a type of white blood cell. ANCA vasculitis can affect different organs or parts of the body, such as the skin, kidney, or lung. The symptoms,...
-
Product Insights
NewAnthrax – Drugs In Development, 2024
Empower your strategies with our Anthrax – Drugs In Development, 2024 report and make more profitable business decisions. Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe bloody diarrhea in the later stages of the disease, sore throat, and difficulty swallowing. Risk factors include illegal intravenous drug use, exposure to animal skins, and working in veterinary medicine, especially dealing with livestock. The Anthrax drugs in development...
-
Product Insights
NewYellow Fever – Drugs In Development, 2024
Empower your strategies with our Yellow Fever – Drugs In Development, 2024 report and make more profitable business decisions. Yellow fever is an acute systemic illness (hemorrhagic fever) caused by a flavivirus. It is spread by mosquitoes. Symptoms include irregular heartbeat, bleeding, vomiting, coma, delirium, fever, headache, and muscle aches. There is no specific treatment for yellow fever, so patients are treated to relieve the symptoms. The Yellow Fever drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewLeishmaniasis (Kala-Azar) – Drugs In Development, 2024
Empower your strategies with our Leishmaniasis (Kala-Azar) – Drugs In Development, 2024 report and make more profitable business decisions. Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen, and fever. Treatment includes anti-parasitic drugs. The Leishmaniasis (Kala-Azar) drugs in development market research report provide comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete...
-
Product Insights
NewLung Adenocarcinoma – Drugs In Development, 2024
Empower your strategies with our Lung Adenocarcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Lung adenocarcinoma is the most common type of non-small cell lung cancer (NSCLC), accounting for a significant portion of lung cancer cases. It typically arises in the outer regions of the lungs and tends to develop in the smaller airways, known as bronchioles. Adenocarcinoma is characterized by cancerous cells that form glandular structures resembling the normal cells found lining the lungs. It...
-
Product Insights
NewTrypanosomiasis – Drugs In Development, 2024
Empower your strategies with our Trypanosomiasis – Drugs In Development, 2024 report and make more profitable business decisions. Trypanosomiasis, also known as sleeping sickness in humans and nagana in animals, is a parasitic disease caused by protozoan parasites of the genus Trypanosoma. There are two main forms of the disease, each caused by different species of Trypanosoma. African trypanosomiasis (sleeping sickness) is transmitted by tsetse flies and is predominantly found in sub-Saharan Africa. It is caused by two subspecies of the...
-
Product Insights
NewPemphigus Vulgaris – Drugs In Development, 2024
Empower your strategies with our Pemphigus Vulgaris – Drugs In Development, 2024 report and make more profitable business decisions. Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender, and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, and skin blisters that come and go. The blisters always occur near the surface of the skin and there is oozing, crusting, or peeling at...